The Effect of Raloxifene on the Incidence of Ovarian Cancer in Postmenopausal Women

By Neven P.   Goldstein S.R.   Ciaccia A.V.   Zhou L.   Silfen S.L.   Muram D.  

Gynecologic Oncology, Vol. 85, Iss. 2, 2002-05 ,pp. : 388-390

Academic Press

Access to resources Recommend Favorite

The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study

By Frechette Dominique   Paquet Lise   Verma Shailendra   Clemons Mark   Wheatley-Price Paul   Gertler Stan   Song Xinni   Graham Nadine   Dent Susan  

Breast Cancer Research and Treatment, Vol. 141, Iss. 1, 2013-08 ,pp. : 111-117

Springer Publishing Company

Access to resources Recommend Favorite

The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) Trial in Postmenopausal Women with Early Breast Cancer – Updated Efficacy Results Based on a Median Follow-up of 47 Months

By Buzdar A.  

Breast Cancer Research and Treatment, Vol. 77, Iss. 3, 2003-02 ,pp. : 295-295

Springer Publishing Company

Access to resources Recommend Favorite

C-reactive protein and postmenopausal breast cancer risk: results from the E3N cohort study

By Dossus Laure   Jimenez-Corona Aida   Romieu Isabelle   Boutron-Ruault Marie-Christine   Boutten Anne   Dupré Thierry   Fagherazzi Guy   Clavel-Chapelon Francoise   Mesrine Sylvie  

Cancer Causes and Control, Vol. 25, Iss. 4, 2014-04 ,pp. : 533-539

Springer Publishing Company

Access to resources Recommend Favorite

Use of raloxifene among women with a history of breast cancer

By Habel Laurel A.   Pressman Alice   Ettinger Bruce   Sidney Stephen   Suh-Burgmann Betty   Fehrenbacher Louis   Quesenberry Charles P.  

Breast Cancer Research and Treatment, Vol. 96, Iss. 2, 2006-03 ,pp. : 123-129

Springer Publishing Company

Access to resources Recommend Favorite